Chimeric models of neurodegenerative diseases: from disease mechanisms to regenerative therapies.
- 1Achucarro Basque Center for Neuroscience, Leioa, Spain.
- 2Department of Neurosciences, University of the Basque Country (EHU), Leioa, Spain.
- 3IKERBASQUE Basque Foundation for Science, Bilbao, Spain.
Abstract
Human-rodent chimeric CNS models provide a unique platform for investigating human-specific aspects of neurodegeneration within the physiological environment of the living CNS. These models are generated by transplanting human pluripotent stem cell-derived neurons, astrocytes, microglia, oligodendrocytes, or neural or glial progenitor cells into the CNS of permissive host animals. Following transplantation, human cells mature, functionally integrate within host tissue, and retain key species-specific molecular and cellular features. Here, we review recent advances in the use of chimeric models to investigate disease mechanisms in Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and demyelinating disorders. We highlight the unique insights these models have provided into human-specific cellular vulnerabilities, genotype-dependent phenotypes, glial responses, and neuroimmune interactions in vivo. We also discuss emerging translational applications, including cell replacement therapies, engineered glial delivery platforms, and remyelination strategies, some of which have progressed toward clinical translation. Finally, we outline the current limitations and future directions for developing next-generation multi-lineage humanized models with enhanced disease fidelity and translational potential.
Related
- Extracellular vesicles in osteoarthritis: pathological mechanisms, regenerative therapies and clinical translation
- Liver X Receptors in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential
- Cuproptosis: New Mechanisms Linking Endothelial Dysfunction to Neurodegenerative Diseases and Therapeutic Prospects
- Epigenetic Mechanisms in Neurodegenerative Diseases: From Genetic Regulation to Therapeutic Potential
- Telomeres, Aging and Neurodegenerative Diseases: Molecular Mechanisms, Clinical Evidence and Therapeutic Perspectives
BibTeX
@article{cacerespalomo2026chimeric,
title = {{Chimeric models of neurodegenerative diseases: from disease mechanisms to regenerative therapies.}},
author = {Laura Cáceres-Palomo and María Alfonso-Triguero and Arantzazu Belloso-Iguerategui and Estibaliz Santiago-Mujika and Marta Mirón-Alcalá and Amaia M Arranz},
journal = {Molecular neurodegeneration advances},
year = {2026},
month = nov,
doi = {10.1186/s44477-026-00059-4},
url = {https://europepmc.org/article/MED/43016791},
note = {CC BY},
}
RIS
TY - JOUR
TI - Chimeric models of neurodegenerative diseases: from disease mechanisms to regenerative therapies.
AU - Laura Cáceres-Palomo
AU - María Alfonso-Triguero
AU - Arantzazu Belloso-Iguerategui
AU - Estibaliz Santiago-Mujika
AU - Marta Mirón-Alcalá
AU - Amaia M Arranz
PY - 2026
DA - 2026/11/10
JO - Molecular neurodegeneration advances
DO - 10.1186/s44477-026-00059-4
UR - https://europepmc.org/article/MED/43016791
AB - Human-rodent chimeric CNS models provide a unique platform for investigating human-specific aspects of neurodegeneration within the physiological environment of the living CNS. These models are generated by transplanting human pluripotent stem cell-derived neurons, astrocytes, microglia, oligodendrocytes, or neural or glial progenitor cells into the CNS of permissive host animals. Following transplantation, human cells mature, functionally integrate within host tissue, and retain key species-specific molecular and cellular features. Here, we review recent advances in the use of chimeric models to investigate disease mechanisms in Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and demyelinating disorders. We highlight the unique insights these models have provided into human-specific cellular vulnerabilities, genotype-dependent phenotypes, glial responses, and neuroimmune interactions in vivo. We also discuss emerging translational applications, including cell replacement therapies, engineered glial delivery platforms, and remyelination strategies, some of which have progressed toward clinical translation. Finally, we outline the current limitations and future directions for developing next-generation multi-lineage humanized models with enhanced disease fidelity and translational potential.
SN - 3059-4944
ER -